DR. SHRINIDHI B,DR. PREM BALAJI LANKAPOTHU,DR. SAI SINDHURI MARUVADA,DR. S PREMKUMAR,DR. ARCHANA P,DR. SARAVANAN
DOI: https://doi.org/Background: A new type of dual GIP/GLP-1 receptor agonist tirzepatide has proven to be very effective in the treatment of type 2 diabetes and obesity conditions and has resulted in tremendous drops in HbA1c levels and body weight. Although it was pharmacologically successful, its actual uptake is affected by other factors other than clinical effectiveness such as patient beliefs, provider attitudes, and other system-related factors. The qualitative systematic review given will focus on the synthesis of the feedback and attitudes of both patients and medical personnel towards the use of Tirzepatide in clinical practice.
Methodology: The systematic literature search was done on March 2025 using PubMed and Google Scholar according to PRISMA. The screening of the studies and the selection of the right ones was based on the established inclusion and exclusion criteria, and the target was the qualitative study on Tirzepatide in the clinical context. Eight studies were found eligible. The extraction of data was conducted in accordance with the CASP Qualitative Checklist, and the process of thematic synthesis was applied with the help of the framework by Thomas and Harden in the determination of analytical themes in the context of participant narratives and interpretations by the authors.
Results: The eight studies that were included were mainly USA, Saudi Arabia and Croatia and although the study participants were diverse, they included patients, dietitians, and general practitioners. Five significant themes came out including (1) emotional and psychological effects of treatment, (2) physical health benefits and perceived effectiveness, (3) motivation and behavior change, (4) support systems and shared decision-making, and (5) the barriers to continuation and concerns. Although patients reported the better confidence, energy, and health outcomes, gastrointestinal side effects, financial barriers, loss of insurance coverage, and reluctance of providers were reported.
Conclusion: The adoption of Tirzepatide in the clinical setting is associated with a multilateral interaction of emotional, physical, social, and systemic factors. Although the drug can be considered as very effective and life-enhancing, its continued use needs to overcome such obstacles as cost, side effects, and familiarity among the providers. Promoting patient-provider communication, providing further training to the providers and equal access to Tirzepatide through policy adjustments are essential to maximize the clinical potential of Tirzepatide. Future research ought to consider the wider demographic representation and the long-term patient participation that would help in informing the collaborative and sustainable implementation planning.
